JP2008502699A - 肺疾患治療方法、及びそのための組成物 - Google Patents

肺疾患治療方法、及びそのための組成物 Download PDF

Info

Publication number
JP2008502699A
JP2008502699A JP2007516702A JP2007516702A JP2008502699A JP 2008502699 A JP2008502699 A JP 2008502699A JP 2007516702 A JP2007516702 A JP 2007516702A JP 2007516702 A JP2007516702 A JP 2007516702A JP 2008502699 A JP2008502699 A JP 2008502699A
Authority
JP
Japan
Prior art keywords
formoterol
pharmaceutically acceptable
solvate
dosage form
potassium channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007516702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008502699A5 (https=
Inventor
エム． スルリバン アンネ
ダブリュー． シモン ジョホン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of JP2008502699A publication Critical patent/JP2008502699A/ja
Publication of JP2008502699A5 publication Critical patent/JP2008502699A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007516702A 2004-06-14 2005-06-14 肺疾患治療方法、及びそのための組成物 Abandoned JP2008502699A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57882804P 2004-06-14 2004-06-14
US60729204P 2004-09-07 2004-09-07
PCT/US2005/021209 WO2005123072A1 (en) 2004-06-14 2005-06-14 Methods and compositions for the treatment of pulmonary diseases

Publications (2)

Publication Number Publication Date
JP2008502699A true JP2008502699A (ja) 2008-01-31
JP2008502699A5 JP2008502699A5 (https=) 2008-07-31

Family

ID=35509446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007516702A Abandoned JP2008502699A (ja) 2004-06-14 2005-06-14 肺疾患治療方法、及びそのための組成物

Country Status (4)

Country Link
US (1) US20080293788A1 (https=)
EP (1) EP1765331A4 (https=)
JP (1) JP2008502699A (https=)
WO (1) WO2005123072A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010113022A1 (ja) * 2009-03-31 2010-10-07 株式会社レナサイエンス プラスミノーゲンアクチベーターインヒビター－1阻害剤
JP2013056925A (ja) * 2012-11-21 2013-03-28 Rottapharm Spa アンドラスト／グルココルチコイドの併用
US8415479B2 (en) 2008-03-31 2013-04-09 Renascience Co., Ltd. Inhibitor of plasminogen activator inhibitor-1
US10092537B2 (en) 2013-04-15 2018-10-09 Renascience Co., Ltd. Use for PAI-1 inhibitor
JP2023504292A (ja) * 2020-04-24 2023-02-02 ヴィコール ファルマ アーベー 経口投与用の新しい遅延放出組成物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077164A1 (en) * 2006-01-06 2007-07-12 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and andolast
PT2054057E (pt) 2006-07-31 2011-05-05 Rottapharm Spa Combina??o de andolast/glucocortic?ides
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202201723D0 (en) * 2022-02-10 2022-03-30 Vicore Pharma Ab New use
WO2023152503A1 (en) 2022-02-10 2023-08-17 Vicore Pharma Ab Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69118359T2 (de) * 1990-01-05 1996-08-14 Sepracor,Inc., Marlborough, Ma. Optisch reines r(-)albuterol zur behandlung von asthma
US5200422A (en) * 1990-09-24 1993-04-06 Neurosearch A/S Benzimidazole derivatives, their preparation and use
US5637470A (en) * 1994-05-13 1997-06-10 Merck & Co., Inc. Screening array using cells expressing recombinant α and β subunits of the mammalian large-conductance (maxi-K) potassium channel
ATE241980T1 (de) * 1997-08-08 2003-06-15 Rotta Research Lab Neue inhalationspräparate enthaltend cr 2039 (andolast)
JP2002523452A (ja) * 1998-08-26 2002-07-30 スミスクライン・ビーチャム・コーポレイション 肺疾患の治療方法
US6656461B1 (en) * 2000-02-29 2003-12-02 The Trustees Of Columbia University In The City Of New York Therapeutic treatment of chronic obstructive pulmonary disease
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US7713964B2 (en) * 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415479B2 (en) 2008-03-31 2013-04-09 Renascience Co., Ltd. Inhibitor of plasminogen activator inhibitor-1
WO2010113022A1 (ja) * 2009-03-31 2010-10-07 株式会社レナサイエンス プラスミノーゲンアクチベーターインヒビター－1阻害剤
US8785473B2 (en) 2009-03-31 2014-07-22 Renascience Co., Ltd. Plasminogen activator inhibitor-1 inhibitor
JP2013056925A (ja) * 2012-11-21 2013-03-28 Rottapharm Spa アンドラスト／グルココルチコイドの併用
US10092537B2 (en) 2013-04-15 2018-10-09 Renascience Co., Ltd. Use for PAI-1 inhibitor
JP2023504292A (ja) * 2020-04-24 2023-02-02 ヴィコール ファルマ アーベー 経口投与用の新しい遅延放出組成物
JP2024001089A (ja) * 2020-04-24 2024-01-09 ヴィコール ファルマ アーベー 経口投与用の新しい遅延放出組成物
JP7418587B2 (ja) 2020-04-24 2024-01-19 ヴィコール ファルマ アーベー 経口投与用の新しい遅延放出組成物
JP7663647B2 (ja) 2020-04-24 2025-04-16 ヴィコール ファルマ アーベー 経口投与用の新しい遅延放出組成物
JP2025106410A (ja) * 2020-04-24 2025-07-15 ヴィコール ファルマ アーベー 経口投与用の新しい遅延放出組成物

Also Published As

Publication number Publication date
WO2005123072A1 (en) 2005-12-29
EP1765331A1 (en) 2007-03-28
EP1765331A4 (en) 2007-12-05
US20080293788A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
JP7621220B2 (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
US8501816B2 (en) Antitussive compositions comprising memantine
ES2762806T3 (es) Tratamiento utilizando estabilizadores de mastocitos para trastornos sistémicos
JP4365106B2 (ja) 医薬配合剤
US20180235931A1 (en) Use of neurokinin-1 antagonists as antitussives
US20040235807A1 (en) Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
JP5941258B2 (ja) 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール
CN102573823B (zh) 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途
ES3029560T3 (en) 5-amino-2,3-dihydro-1,4-phthalazinedione as glucocorticoid-sparing agent
KR20010034703A (ko) 플루옥세틴과 이의 거울상이성질체의 안정한 약형
JP2008502699A (ja) 肺疾患治療方法、及びそのための組成物
JP2008502698A (ja) アルブテロール、及びカルシウム活性化カリウムチャネルオープナーの使用方法。
CA2570448A1 (en) Methods and compositions for the treatment of pulmonary diseases
JP7854206B2 (ja) 肺線維症の予防または治療用の薬学製剤
TR201611685A1 (tr) Oral farmasöti̇k terki̇pler
TR201612324A1 (tr) Solunum Yolu Hastalıklarında Kullanılan Farmasötik Terkipler
US20240082176A1 (en) Dropropizine in combination with ambroxol in the dosage form of syrup and tablets
AU2011236040A1 (en) (R,R)-Formoterol in combination with other pharmacological agents
TR201612582A1 (tr) Oral farmasöti̇k terki̇pler
TR201611687A1 (tr) Oral farmasöti̇k terki̇pler
TR201611756A2 (tr) Oral farmasöti̇k terki̇pler
CZ340699A3 (cs) Farmaceutický prostředek s obsahem norastemizolu

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080611

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20100409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100409